

May 31st, 2024 at 12:00 a.m. (CET)
At Vandoeuvre-lès-Nancy - FRANCE

ETAP-Lab at 2024 BIO International Convention: Presenting an enriched preclinical model portfolio with new *in vivo* models.

ETAP-Lab - a preclinical CRO - will attend the upcoming 2024 BIO International Convention on next June 3 – 6, 2024, in San Diego, California for partnering opportunities and presenting its innovations.

ETAP-Lab is a French preclinical CRO recognised for 30 years for its high-level research services - in Dermatology, Neurology, Gastroenterology and Cardiology – that **support its customers' pharmacological research** for the benefit of human health.

Our team at the convention, with the support of the French delegation

Thanks to the **HealthCare innovation France 2030 plan**, we participate to BIO in the French delegation made up with companies at the forefront of innovation. Our French partners that support us in this Business adventure are CCI International Grand Est, Business France Healthcare and Eurobiomed. This year our company will be represented by **Dr. Jérôme BERNARD** and **Dr. Sandra ROBELET** during BIO's One-on-One Partnering™.

New *in vivo* preclinical services

With the **recent incorporation of SYNCROSOME** in late 2023, the company can now propose a brand-new ***in vivo* Parkinson's disease model** as well as a large **preclinical cardiorespiratory offer**, hence strengthening the global *in vivo* model portfolio.

An enriched preclinical model portfolio

ETAP-Lab's, along with its brands SYNCROSOME & STROK@LLIANCE, can accelerate, derisk and support preclinical development thanks to relevant & translatable ***in vitro* and *in vivo* models**. The company proposes a **consolidated portfolio of models** in Dermatology (for inflammatory pathologies & wound healing...), in Neurology (for stroke, neurodegenerative disease like Parkinson's and Alzheimer's, and psychopharmacology), in Gastroenterology (for gastrointestinal & metabolic disturbances) and in Cardiology (for Pulmonary Arterial Hypertension and heart failure - HFrEF, HFpEF, ...). Using state-of-the-art techniques, advanced imaging tools (MRI, PET-Scan) and our histology and immunohistochemistry platforms, ETAP-Lab offers better predictability of therapies and medical devices efficacy.

Beyond expertise, the flexible and human-sized organization allow to design and operate **tailored drug efficacy studies** to fit client's needs.

About ETAP-Lab - www.etap-lab.com

ETAP-Lab is an independent contract research organisation (CRO) based in Vandœuvre-lès-Nancy (France) since 1991. It carries out preclinical studies to develop innovative molecules and components for pharmaceutical and biotechnology companies, particularly in the fields of neurodegenerative diseases, stroke, cardiorespiratory and dermatology.

Contact

Marketing & press relation
+33 383 444 635 - marketing@etap-lab.com

###